Results 101 to 110 of about 2,000 (177)

Resistance Analyses of Lenacapavir, Emtricitabine/Tenofovir Alafenamide and Emtricitabine/Tenofovir Disoproxil Fumarate in the PURPOSE 1 and 2 Studies

Journal of Infectious Diseases
Background Lenacapavir (LEN) is an HIV-1 capsid inhibitor being evaluated for pre-exposure prophylaxis (PrEP). The PURPOSE trials assessed the efficacy of LEN and emtricitabine/tenofovir disoproxil fumarate (F/TDF) in cisgender women (PURPOSE 1; P1) and ...
S. Cox, Kristen Andreatta, Matthew R Hendricks, Jia-Ni Li, Alexander Kintu, Lillian B Brown, Christoph C. Carter, Christian Callebaut   +7 more
semanticscholar   +1 more source

Expanding Treatment Opportunities: Reviewing the Current State of Injectable Antiretrovirals for Treatment of HIV

Infectious Diseases and Therapy
Antiretroviral therapy has evolved significantly over the last 20–30 years, from requiring multiple tablets multiple times per day to single-tablet regimens and most recently, in 2021, long-acting injectable antiretrovirals.
Amanda Binkley, Matty Zimmerman, Christina Maguire   +2 more
doaj   +1 more source

Effects of GS-CA1 on nuclear envelope-associated early HIV-1 infection steps

Frontiers in Virology
The novel HIV-1 drugs GS-CA1 and the recently approved lenacapavir (GS-6207) target the viral structural protein capsid (CA). However, their multiple mechanisms of action have not been fully characterized.
Amita Singh, Victor Fourcassié, Victor Fourcassié, Karen Cristine Gonçalves Dos Santos, Hocine Chelbi, Natacha Merindol, Arnaud Droit, Arnaud Droit, Hugo Germain, Lionel Berthoux   +9 more
doaj   +1 more source

Pharmacokinetics, pharmacodynamics, efficacy and drug resistance selection of injectable long-acting lenacapavir pre-exposure prophylaxis (PrEP) against HIV

medRxiv
Oral pre-exposure prophylaxis (PrEP) denotes an effective strategy to reduce the risk of HIV infection. However, many individuals encounter difficulties adhering to the once-daily regimen, which highlights the need for a broader portfolio of PrEP options.
Hee-yeong Kim, Antonia Liebenberg, Lan-Xin Zhang, M. von Kleist   +3 more
semanticscholar   +1 more source

Multi-Center Real-World Implementation Outcomes of Lenacapavir for HIV Pre-Exposure Prophylaxis

Lenacapavir PrEP implementation across 17 U.S. sites (n=501) was characterized by delays in initiation driven by payer processes. Early non-persistence was uncommon (3.6%) but exceeded clinical trial discontinuation rates and was strongly associated with
Cannon, Chase A, Narcisse-Cempini, Gilianne, Multani, Ami, Gipson, June, Turner, Christian, Kunzmann, Leah, Chan, Philip A, Clement, Meredith, Spinelli, Matthew, Havens, Joshua P, Springer, Sandra A, Cherabie, Joesph, Lillis, Rebecca, Taraschi, Ellen, Butler, Isolde, Vail, Rona, Sukumaran, Stephen, Patel, Rupa R, Hazra, Aniruddha, Blumenthal, Jill, Kaperak, Christopher J, Doblecki-Lewis, Susanne, Smith, Romini, Halbur, Drew, Safa, Hussein   +24 more
core   +1 more source

Noticiero farmacológico

Revista del Hospital de Niños
Sección a Cargo de Patricia Cardoso y Raúl Plager Caspofungina: evitar membranas derivadas de poliacrilonitrilo durante el tratamiento sustitutivo renal continuo. Dinutuximab beta: síndrome urémico hemolítico atípico.
Patricia Cardoso, Raúl Plager
doaj   +2 more sources

Preparation of a Key Intermediate En Route to the Anti-HIV Drug Lenacapavir

A very efficient four-step synthesis of the main fragment of Gilead’s anti-HIV drug lenacapavir is described. The route showcases a 1,2-addition to an intermediate aldehyde using an organozinc halide derived from a commercially available difluorobenzyl ...
Yuting Hu (322619), Bruce H. Lipshutz (1330881), Juan C. Caravez (12495731), Erfan Oftadeh (17797153), Kirubel T. Mamo (18115323)   +4 more
core   +1 more source

Acceptability and Implementation Considerations for Twice-Yearly Injectable Lenacapavir PrEP in Kazakhstan: An Exploratory Mixed-Methods Study

This exploratory mixed-methods study examines acceptability of twice-yearly injectable lenacapavir for HIV pre-exposure prophylaxis (PrEP) among key populations (gay, bisexual, and other men who have sex with men; people who use drugs; sex workers ...
Indira Karibayeva, Gulmira Abdiraiymova, Sholpan Primbetova, Assel Terlikbayeva, Janina Steinert, Elena German, Sairankul Kassymbekova, Susanna Rinne-Wolf, Akhan Nurtazin, Nikolay Lunchenkov, Aruzhan Saimasova   +10 more
core   +1 more source

PP 5.2 – 00072 Simulations for Once Weekly Dosing of Oral Lenacapavir

Journal of Virus Eradication, 2022
N. Shaik, H. Zhang, S. Girish, M. Rhee, R. Palaparthy, A. Karimzadeh, R. Singh   +6 more
doaj   +1 more source

Lenacapavir Use in France: A National, Observational Study (LENAddOn). [PDF]

Open Forum Infect Dis
Ghosn J, Pourcher V, Allavena C, Hocqueloux L, Lacombe K, Cua E, Bonnet F, Duvivier C, Makinson A, Jacomet C, Lascoux C, Viard JP, Robineau O, Hentzien M, Teicher E, Pialoux G, Abgrall S, Cazanave C, Cabié A, Dudoit Y, Peytavin G, Barrière G, Dunn K, Marcelin AG, Assoumou L, Palich R, LENAddOn Study Group, LENAddOn Study Group .   +27 more
europepmc   +1 more source